Paper Details

  1. Home
  2. Paper Details

Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial.

Author: AdamczykRobert, BlackmanNicole, ButlerJaved, De PasqualeCarmine G, EzekowitzJustin A, GargJyotsna, HarringtonJosephine, HernandezAdrian F, LewisGregory D, MentzRobert J, O'MearaEileen, PonikowskiPiotr, RockholdFrank W, TroughtonRichard W, WongYee Weng

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The HEART-FID study, investigating intravenous iron in patients with heart failure (HF) and iron deficiency, has enrolled a large and diverse cohort. Participants had similar baseline demographics and clinical characteristics to those in other contemporary HF with reduced ejection fraction (HFrEF) trials.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Prior clinical trials have investigated intravenous iron in patients with heart failure (HF) and iron deficiency, but the safety and efficacy of this therapy remains unclear. METHODS: We report the baseline demographics and clinical characteristics of patients enrolled in the HEART-FID ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ahj.2023.08.005

データ提供：米国国立医学図書館（NLM）

Baseline Characteristics of Patients in the Randomized Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency

Imagine the heart as a tireless desert camel, carrying the burden of life's journey. This research explores the potential benefits of iron supplementation for patients with heart failure who are also iron deficient. It's like providing a much-needed boost of energy to a weary camel, helping it continue on its journey. Researchers conducted a large clinical trial to investigate the safety and efficacy of ferric carboxymaltose, an intravenous iron preparation, in patients with heart failure and iron deficiency.

Understanding the Landscape of Heart Failure

The study meticulously documented the characteristics of the patients enrolled in the trial, providing a valuable snapshot of this diverse population. The researchers found that the patients in the study had similar demographics and clinical characteristics to those in previous heart failure trials, like observing a consistent pattern of desert landscapes. This comprehensive baseline assessment lays the foundation for evaluating the effectiveness and safety of ferric carboxymaltose in treating heart failure with iron deficiency.

Hope for a Stronger Heart

This research holds promise for improving the lives of patients with heart failure and iron deficiency. It's like discovering a hidden oasis that can replenish the camel's strength and enable it to continue its journey with renewed vigor. By understanding the characteristics of this patient population and the potential benefits of iron supplementation, we can explore new avenues for treatment and support, ultimately leading to better outcomes for those struggling with heart failure.

Dr. Camel's Conclusion

This study, like a well-equipped caravan, provides a detailed picture of the diverse landscape of heart failure with iron deficiency. It sets the stage for exploring the potential benefits of iron supplementation, offering hope for a stronger heart and a smoother journey through the challenges of heart failure.

Date :
  1. Date Completed 2023-11-27
  2. Date Revised 2023-12-08
Further Info :

Pubmed ID

37598795

DOI: Digital Object Identifier

10.1016/j.ahj.2023.08.005

Related Literature

Article Analysis
・Effective treatment of iron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.